- Open Access
Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies
Clinical and Translational Allergy volume 6, Article number: 32 (2016)
Patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) report difficulty with sleep.
We examined the effect of omalizumab on sleep-related outcomes during 3–6 months omalizumab or placebo treatment and a 16-week follow-up period within three Phase III double-blind randomized placebo-controlled pivotal trials in CIU/CSU: ASTERIA I, ASTERIA II, and GLACIAL. Sleep quality was assessed in all three studies using sleep-related questions included in an electronic diary, the Chronic Urticaria Quality of Life Questionnaire, and the Medical Outcomes Study Sleep Scale. Score changes from baseline in the treatment arms were compared with that in the placebo arm and adjusted for baseline score and weight. We also examined correlations of sleep scores at baseline, week 12, and week 24 and the slopes of change between sleep and itch and hive.
Patients treated with omalizumab reported a larger reduction in sleep problems than those in the placebo arm; omalizumab 300 mg demonstrated the greatest improvement on all sleep components among all treatment arms. The largest reduction in sleep problems was reported within the first 4 weeks of therapy. After treatment discontinuation, sleep quality worsened. Sleep scores demonstrated moderate-to-strong correlation between them, and the change in sleep scores was associated with changes in itch and hives.
Improvement in sleep was reported after the first dose of omalizumab. Sleep continued to improve throughout the active treatment period. Patients receiving omalizumab 300 mg achieved greater improvement in sleep than those in other treatment arms.
Trial registration ClinicalTrials.gov, NCT01287117 (ASTERIA I), NCT01292473 (ASTERIA II), and NCT01264939 (GLACIAL)
The Institute of Medicine has warned that chronic sleep disorder and wakefulness adversely impact health and longevity . Many chronic conditions are associated with impairments of sleep quantity or quality [2–5]. Chronic idiopathic urticaria (CIU), also known as chronic spontaneous urticaria (CSU), is a disorder characterized by chronic hives, itch, and often angioedema that may lead to difficulty initiating or maintaining sleep or poor sleep quality [6–12]. CIU/CSU patients reported that the presence of hives, itching, or both prevented adequate sleep [7–11]. In these patients, poor sleep causes fatigue and diminishes physical and emotional well-being . In an Internet survey of patients with chronic urticaria, 48 % of respondents reported that sleep disturbances related to chronic urticaria were not adequately addressed . When compared with patients with heart disease, patients with chronic urticaria report more difficulty with sleep disruption .
Omalizumab is a humanized anti-immunoglobulin E antibody indicated for CIU/CSU in adults and adolescents who remain symptomatic despite H1-antihistamine treatment , as reported in the pivotal clinical studies [14–16]. Omalizumab, 150 or 300 mg, given as an every-4-week subcutaneous injection, significantly reduces disease activity, improves CIU/CSU symptoms, and is well tolerated in patients with refractory CIU/CSU symptoms. The 2013 international guidelines recommend the addition of omalizumab (150–300 mg) to current treatment for CIU/CSU patients who remain symptomatic despite receiving high doses of H1-antihistamines . Phase III omalizumab CIU/CSU clinical studies collected sleep quality data via patient-reported outcome measures. We investigated the following research question: to what extent do sleep outcomes improve in CIU/CSU patients treated with omalizumab during 3 to 6 months within these three pivotal studies?
The omalizumab pivotal studies included ASTERIA I, ASTERIA II, and GLACIAL. Full study details are summarized elsewhere [14–16]. Briefly, each study included patients aged 12–75 years (18–75 years in Germany per regulatory requirements) with CIU/CSU who remained symptomatic despite treatment with background therapy. ASTERIA I and II allowed up to approved doses of H1-antihistamine [14, 16], while GLACIAL included patients being treated with up to 4 times approved doses plus H2-antihistamines, leukotriene receptor antagonists, or both . In ASTERIA I and II, patients were randomized 1:1:1:1 to receive omalizumab 75, 150, 300 mg, or placebo subcutaneously every 4 weeks. Patients included in GLACIAL were randomized 3:1 to receive omalizumab 300 mg or placebo every 4 weeks. Dosing continued for 24 weeks in ASTERIA I and GLACIAL and for 12 weeks in ASTERIA II. Diphenhydramine 25 mg (up to 3 doses in 24 h) was allowed as a rescue medication for itch relief in all three studies.
In all three studies, patients were followed for an additional 16 weeks of observation after the end of the treatment period. Studies were conducted in accordance with US Food and Drug Administration regulations, the International Conference on Harmonisation E6 Good Clinical Practice guidelines, the principles of the Declaration of Helsinki, and any other applicable country laws. Study protocols were reviewed and approved by each institutional review board and all patients provided informed consent before study entry. The studies were registered with ClinicalTrials.gov, identifiers NCT01287117 (ASTERIA I), NCT01292473 (ASTERIA II), and NCT01264939 (GLACIAL).
Patients were eligible for study inclusion if they met individual study age and background therapy requirements. Patients had a diagnosis of CIU/CSU for at least 6 months and presence of itch and hives for at least 8 (ASTERIA I and II) or more than 6 (GLACIAL) consecutive weeks before enrollment despite concurrent CIU/CSU therapy.
Patients reported their CIU/CSU symptoms and their impact on daily activities and sleep via an electronic daily diary  and paper-based patient-reported outcomes during office visits [baseline, weeks 4, 12, and 28 (ASTERIA II), and weeks 4, 12, 24, and 40 (ASTERIA II and GLACIAL)]. Individual study publications provide additional details on the study design [14–16].
Sleep quality was assessed in all three studies via one question in the electronic diary , several questions in the Medical Outcomes Study Sleep Scale (MOS-Sleep Scale) , and the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) .
In the Urticaria Patient Daily Diary (UPDD), a Sleep Interference question prompts patients to report the extent to which itch or hives interfered with their sleep in the previous 24 h (score range 0–3: 0 = no interference; 1 = mild, little interference with sleep; 2 = moderate interference, awoke occasionally, some interference with sleep; 3 = substantial, awake often, severe interference with sleep) . A Weekly Sleep Interference Score (range 0–21) is the sum of the daily scores; a higher score indicates greater sleep interference. The UPDD has been validated in adults and adolescents with CIU/CSU [18, 21].
The MOS-Sleep Scale is a 12-item measure of sleep quality within a 4-week recall period . The MOS-Sleep Scale has been validated in other disease areas, including diabetic neuropathic pain . An MOS-Sleep scale score of 25.8 has been noted to be the population norm . The MOS-Sleep Scale, Sleep Problem Index II (SPI-II) includes nine questions assessing sleep disturbance, sleep adequacy, somnolence, snoring, and awakening with shortness of breath or headache. SPI-II scores range from 0 to 100, with a higher number reflecting greater difficulty with sleep.
The CU-Q2oL is a 23-item questionnaire to measure quality of life in patients with chronic urticaria with a 2-week recall period . The Sleep Problems dimension contains five questions about the extent to which urticaria has affected limited sleep, difficulty falling asleep, waking up during the night, tiredness during the day due to lack of sleep, difficulties with concentration, and feeling nervous. Each of item is scored on a five-point scale ranging from 1 (not at all) to 5 (extremely); thus the total scoring for this dimension ranges from 5 (least difficulty with sleep) to 25 (most difficulty with sleep).
We compared the changes in MOS-Sleep Scale, UPDD Weekly Sleep Interference Score, and CU-Q2oL Sleep Problems domain scores from Baseline to each measurement point in the treatment arms with those in the placebo arms using analysis of covariance t tests, which were adjusted for baseline score (less than median, greater than or equal to median) and weight (<80, ≥80 kg) and individually fit at each time point. All statistical analyses were performed with SAS software (version 9.1; SAS Institute Inc., Cary, NC, USA).
We used Pearson correlation coefficient to estimate simple correlations among sleep outcomes in all three studies (pooled). We also explored the correlations between the trajectories of change in the Weekly Urticaria Activity Score (UAS7) and two domains of the MOS Sleep Scale (daytime somnolence and sleep disturbance) in the three studies. For that, we used latent growth modeling , wherein individual slopes of change and intercepts for UAS7 and MOS daytime somnolence and sleep disturbance were correlated for each patient.
To adjust for the use of diphenhydramine (as a rescue medication) and to properly model the correlated nature of within-patient observations over time, we conducted sensitivity analyses for the UPDD results using repeated-measures models, which adjusted for baseline score, weight, and weekly diphenhydramine dose as a time-varying covariate. A range of covariance structures was considered in fitting these repeated-measures models, all of which yielded very similar results. The final results presented are extracted from the models that used Toeplitz covariance structures, which assume that observations equally spaced in time have the same covariance.
Baseline patient characteristics have previously been reported [14–16]. At Baseline, patients with CIU/CSU reported substantial sleep impairment, with mean MOS-Sleep Scale, SPI-II scores ranging from 47.4 to 49.2, mean UPDD Weekly Sleep Interference Scores ranging from 11.2 to 12.6, and mean CU-Q2oL Sleep Problems domain scores ranging from 45.1 to 49.4 (Table 1).
On average, patients with CIU/CSU in all treatment arms experienced improvement in sleep at week 12 compared with Baseline for all sleep measures (Table 2). Patients treated with omalizumab reported a larger reduction in sleep problems than those in the placebo arm, and omalizumab 300 mg demonstrated best results among all study arms as noted in Table 2 [statistically significant improvement with omalizumab 300 mg at week 12 for MOS-Sleep Scale (all three studies), UPDD Weekly Sleep Interference Score (ASTERIA I and GLACIAL), and CU-Q2oL Sleep Problems domain (GLACIAL)]. Patient sleep improved quickly; the largest reduction in sleep problems was reported within the first 4 weeks of therapy and were maintained over the active treatment period. The patterns of sleep improvement are presented below according to each medium of assessment.
UPDD Weekly Sleep Interference Scores
As assessed through the UPDD Weekly Sleep Interference Score, patients reported improvement in sleep as early as week 1, and the most dramatic improvement was observed by week 4 (Fig. 1). Further sleep improvement was reported by week 12, and beyond, by week 24 (in ASTERIA I and GLACIAL). During active treatment in all three studies, the omalizumab 300 mg arm demonstrated the largest improvement compared with all other treatment arms as noted in Fig. 1 (statistical significance with omalizumab 300 mg at all time points during active treatment in all three studies). After the active treatment period during which improvements had been observed, all omalizumab-treated patients experienced a relapse in symptoms, including sleep, although the scores did not fully return to baseline values. Placebo-treated patients who had not experienced a substantial improvement in sleep measures during the active treatment period, continued with stable symptoms during the follow-up period.
Sensitivity analyses demonstrated similar trends in the data; sleep systematically improved over the course of the study, and the omalizumab 300 mg arm demonstrated the best outcomes (Additional file 1: Figure S1).
MOS-Sleep Scale, SPI-II scores
MOS-Sleep Scale, SPI-II scores reflected improvement in sleep at the first time of measurement, week 4, after which the improvement in sleep was maintained until weeks 12 (all studies) and 24 (ASTERIA I and GLACIAL; Fig. 2). In all studies, omalizumab 300 mg demonstrated the largest improvement compared with the other treatment arms as noted in Fig. 2 (statistically significant improvement with omalizumab 300 mg at all measured time points during active treatment in all three studies) (Fig. 3).
Through the CU-Q2oL questionnaire Sleep Problems domain, patients reported the most dramatic improvement in sleep at the first time of assessment (week 4). Afterwards, the improvement in sleep was maintained or slightly improved through weeks 12 (all studies) and 24 (ASTERIA I and GLACIAL; Fig. 3). In all three studies, sleep improvement was greatest with omalizumab 300 mg as noted in Fig. 5 (statistically significant improvement with omalizumab 300 mg at all measured time points during active treatment in ASTERIA II and GLACIAL and at weeks 4 and 8 in ASTERIA I).
The correlations between sleep outcomes (Table 3) ranged from moderate to strong. The strongest correlation at all time-points was between CU-Q2oL and MOS Sleep Scale, Sleep Problem Index-II, possibly reflecting longer recall period (2 and 4 weeks, respectively) and broader scope of questions than in UPDD Weekly Sleep Interference Score, obtained through UPDD, which was completed daily. Latent curve modeling revealed correlation between changes in the disease activity and changes in sleep. Individual-level changes in UAS7 and MOS daytime somnolence were moderately to strongly correlated in ASTERIA I and GLACIAL (Fig. 4). Individual-level changes in the UAS7 and MOS sleep disturbance were moderately correlated in ASTERIA I and GLACIAL (Fig. 5). In other words, improvement in itch and hives was associated with decreases in somnolence and sleep disturbance.
Data from the three pivotal studies of omalizumab demonstrated substantial sleep improvement in patients with CIU/CSU. Marked improvement in sleep scores was observed after the first dose of therapy. As assessed by the three scales, the omalizumab 300 mg arms demonstrated the greatest improvements among all treatment arms. These results suggest that for patients with CIU/CSU and disturbed sleep, omalizumab should be considered as a potential treatment option, especially if the underlying CIU/CSU is uncontrolled despite H1-antihistamines.
Sleep disturbances in dermatologic disorders may substantially impair health-related quality of life and may be associated with serious psychopathology . Sleep disorders in dermatologic conditions may result not only because of symptoms such as pruritus causing difficulties initiating or maintaining sleep (e.g., insomnia), but also through other physiologic mechanisms, including disruption of the skin’s thermoregulatory function [25, 26]. The treatment of sleep disturbance in dermatologic disorders such as atopic dermatitis has received considerable attention, but the impacts of treatment on sleep disturbance in CIU/CSU have not been well elucidated . Moreover, treatments of sleep disturbance in dermatologic disorders often focus on response to sedating medications such as hypnotics rather than treatment of the underlying condition . Therefore, it is notable that we observed improvements in sleep by targeting the underlying dermatologic disorder.
Grob et al.  reported on sleep impairment in 1356 adult patients with chronic skin disorders; three groups of patients were represented: chronic urticaria, psoriasis, and atopic dermatitis. Interference with sleep described as “often” or “every night” was reported by more than 50 % of patients with chronic urticaria. Sleeping was more problematic in patients with chronic urticaria and psoriasis than in those with atopic dermatitis. The baseline characteristics of our patient population with refractory CIU/CSU symptoms confirm that sleep impairment is problematic for these patients as reflected by measurement with the three patient-reported outcome measurement tools (MOS-Sleep Scale, SPI-II; UPDD Weekly Sleep Interference Score; and CU-Q2oL Sleep Problems domain).
Although sedating H1-antihistamines work as nighttime therapy for CIU/CSU (to relieve symptoms and help with sleep), some patients report their itch and hives persist despite such treatment. Over-the-counter diphenhydramine lacks consensus recommendation in the treatment of chronic insomnia, and some have questioned its efficacy and safety . ASTERIA I and ASTERIA II demonstrated a dose-dependent reduction in the mean number of diphenhydramine tablets/week as compared with placebo at Week 12 (ASTERIA I: placebo, −1.00; 75 mg, −2.29, p = 0.1356; 150 mg, −2.94, p = 0.0249; 300 mg, −4.20, p = 0.0001; ASTERIA II: placebo, −2.21; 75 mg, −2.33, p = 0.9120; 150 mg, −3.72, p = 0.0682; 300 mg, −4.14, p = 0.0138); the reduction in GLACIAL was not significant (placebo, −2.70, 300 mg, −3.92, p = 0.1499). All enrollees in our clinical studies were patients with moderate to severe CIU/CSU who failed at least 6 weeks of therapy with licensed doses of H1-antihistamines. In GLACIAL, H1-antihistamines could be used at up to four times the approved dose, increasing the possibility of producing a sedating effect. This is consistent with previous reports that as much as 50 % of patients with CIU/CSU (especially with moderate to severe urticaria) fail to respond to up to four times the approved dose of H1-antihistamines [6, 29, 30].
Omalizumab use in these patients resulted in improved sleep, and this effect was persistent beyond the H1-antihistamine background therapy. In GLACIAL, patients were allowed to take an H1-antihistamine at up to four times the approved dose plus H2-antihistamines, leukotriene receptor antagonists, or both. In ASTERIA I, patients were allowed to add 1 additional H1-antihistamine at approved dosing after week 12. Omalizumab 300 mg demonstrated the best results throughout the duration of the study, with the omalizumab 300 mg arms exhibiting notable improvement in sleep and retaining it through the end of the active treatment period.
Sleep improvement recorded via UPDD Weekly Sleep Interference scores appeared to be more pronounced than those recorded via CU-Q2oL or MOS-SS. Moreover, the scores of the latter two instruments correlated stronger between themselves than they did with the WSI scores. This may appear counter-intuitive in light of the fact that MOS-SS is a sleep-specific instrument. The root of this phenomenon may lay in the intricacies of the disease and instruments’ ability to detect change. Because CIU/CSU symptoms can wax and wane throughout a course of days and even hours, daily symptoms capture offered by the eDiary (the tool used to collect data from WSI scores) rendered more accurate picture of the drug effect on the disease than the CU-Q2oL and MOS-SS. Because their recall periods comprise 2 and 4 weeks, respectively, CU-Q2oL and MOS-SS instruments tend to capture the “overall sleep” picture as opposed to the volatility of sleep directly related to CIU/CSU.
Results should be interpreted in light of limitations. Minimally important clinical differences for changes in sleep measures have not been established in patients with CIU/CSU. These analyses are limited by the treatment period of the clinical studies; response to treatment for extended periods is not known. Also, the use of over-the-counter sleep aids was not measured in our study. Additionally, although the improvements in patients’ underlying CIU/CSU would seem to suggest that this is the etiology of improved sleep, we cannot determine the extent to which this may have been because of reduced pruritus versus other potential etiologies, such as a more direct physiologic effect of improved dermatologic health. However, improvements in symptoms of CIU/CSU associated with omalizumab treatment in the Phase III trials have been shown to correlate closely with improvements in health-related quality of life .
Patients with CIU/CSU commonly reported sleep impairment at Baseline. Patients treated with omalizumab reported improvement in sleep after the first dose of omalizumab. Sleep continued to improve with subsequent doses, and sleep improvement was evident until the end of the active treatment period. The return of disease symptoms following discontinuation of active treatment was accompanied by a resurgence of sleep impairment. Patients receiving omalizumab 300 mg achieved greater improvement in sleep than those in other treatment arms.
chronic idiopathic urticaria
chronic spontaneous urticaria
Chronic Urticaria Quality of Life Questionnaire
- MOS-Sleep Scale:
Medical Outcomes Study Sleep Scale
Sleep Problem Index II
Urticaria Patient Daily Diary
Institute of Medicine Committee on Sleep Medicine and Research. Sleep disorders and sleep deprivation: an unmet public health problem. Washington, DC: The National Academy of Sciences; 2006. http://iom.nationalacademies.org/~/media/Files/Report%20Files/2006/Sleep-Disorders-and-Sleep-Deprivation-An-Unmet-Public-Health-Problem/Sleepforweb.pdf. Accessed 9 Nov 2015.
Foley D, Ancoli-Israel S, Britz P, Walsh J. Sleep disturbances and chronic disease in older adults: results of the 2003 National Sleep Foundation Sleep in America Survey. J Psychosom Res. 2004;56:497–502.
Ford ES, Cunningham TJ, Giles WH, Croft JB. Trends in insomnia and excessive daytime sleepiness among U.S. adults from 2002 to 2012. Sleep Med. 2015;2015(16):372–8.
Gezer O, Batmaz I, Sariyildiz MA, Sula B, Ucmak D, Bozkurt M, et al. Sleep quality in patients with psoriatic arthritis. Int J Rheum Dis. 2014. doi:10.1111/1756-185X.12505.
Westhovens R, Van der Elst K, Matthys A, Tran M, Gilloteau I. Sleep problems in patients with rheumatoid arthritis. J Rheumatol. 2014;41:31–40.
Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011;66:317–30.
Baiardini I, Giardini A, Pasquali M, Dignetti P, Guerra L, Specchia C, et al. Quality of life and patients’ satisfaction in chronic urticaria and respiratory allergy. Allergy. 2003;58:621–3.
Grob JJ, Revuz J, Ortonne JP, Auquier P, Lorette G. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol. 2005;152:289–95.
Maurer M, Ortonne J-P, Zuberbier T. Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients. Br J Dermatol. 2009;160:633–41.
O’Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136:197–201.
Yosipovitch G, Ansari N, Goon A, Chan YH, Goh CL. Clinical characteristics of pruritus in chronic idiopathic urticaria. Br J Dermatol. 2002;147:32–6.
Vietri J, Turner SJ, Tian H, Isherwood G, Balp MM, Gabriel S. Effect of chronic urticaria on US patients: analysis of the National Health and Wellness Survey. Ann Allergy Asthma Immunol. 2015;115:306–11.
Xolair® (omalizumab) [prescribing information]. San Francisco: Genentech; 2014. http://www.gene.com/download/pdf/xolair_prescribing.pdf. Accessed 9 Nov 2015.
Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132:101–9.
Maurer M, Rosén K, Hsieh H-J, Saini S, Grattan C, Gimenéz-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–35.
Saini SS, Bindslev-Jensen C, Maurer M, Grob J-J, Basken EB, Bradley MS, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135:925.
Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868–87.
Mathias SD, Dreskin SC, Kaplan A, Saini SS, Spector S, Rosén KE. Development of a daily diary for patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2010;105:142–8.
Hays R, Stewart A. Sleep measures. In: Stewart A, Ware J, editors. Measuring functioning and well-being: the Medical Outcomes Study approach. Durham: Duke University Press; 1992. p. 235–9.
Baiardini I, Pasquali M, Braido F, Fumagalli F, Guerra L, Compalati E, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: Chronic Urticaria Quality of Life Questionnaire (CU-QoL). Allergy. 2005;60:1073–8.
Mathias SD, Tschosik EA, Zazzali JL. Adaptation and validation of the Urticaria Patient Daily Diary for adolescents. Allergy Asthma Proc. 2012;33:186–90.
Viala-Danten M, Martin S, Guillemin I, Hays RD. Evaluation of the reliability and validity of the Medical Outcomes Study Sleep Scale in patients with painful diabetic peripheral neuropathy during an international clinical trial. Health Qual Life Outcomes. 2008;6:113.
Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the Medical Outcomes Study Sleep measure. Sleep Med. 2005;6:41–4.
Stull DE. Analyzing growth and change: latent variable growth curve modeling with an application to clinical trials. Qual Life Res. 2008;17:47–59.
Gupta MA, Gupta AK. Sleep-wake disorders and dermatology. Clin Dermatol. 2013;31:118–26.
Beltrani V. Clinical features of atopic dermatitis. Immunol Allergy Clin N Am. 2002;22:25–42.
Kelsay K. Management of sleep disturbance associated with atopic dermatitis. J Allergy Clin Immunol. 2006;118:198–201.
Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4:487–504.
Asero R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin Exp Dermatol. 2007;32:34–8.
Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125:676–82.
Stull DE, McBride D, Houghton K, Finlay AY, Gnanasakthy A, Balp MM. Assessing changes in chronic spontaneous/idiopathic urticaria: comparisons of patient-reported outcomes using latent growth modeling. Adv Ther. 2016;33:214–24.
AGA-A, TM, KR, and BT participated in the clinical trials: KR and BT as sponsors and AGA-A and TM as investigators. EA, KR, BT, DS, and MB were involved with data analyses. All authors participated in data interpretation. All authors contributed to the drafting or revising of the manuscript, and all authors, except SS, approved the final version of the manuscript.
We would like to acknowledge the sad passing of Sheldon Spector on December 29th, 2015; because of that Dr. Spector was unable to provide input and approval of the revised version of the manuscript. The funding for ASTERIA I, ASTERIA II, and GLACIAL was provided by Genentech, Inc., South San Francisco, CA, USA and Novartis Pharma AG, Basel, Switzerland. The funding for this study was provided by Genentech, Inc. Medical writing support for this manuscript was provided by Charlotte Kenreigh of Excel Scientific Solutions and funded by Genentech, Inc. and Novartis Pharmaceuticals Corporation.
AG-A has received payments for serving on advisory boards from Genentech, Novartis, Uriach Pharma, Almirall, Basilea, GlaxoSmithKline and Unilever, lecture fees from Novartis, Almirall, Bayer-Intendis, and Uriach Pharma, payments for the development of educational presentations from Novartis, Menarini and GlaxoSmithKline, and grant support through her institution from Uriach Pharma, Bayer-Intendis, Novartis and Inescop. SS had stock and mutual funds in GlaxoSmithKline and Merck; had received grant support from Amgen, AstraZeneca, Boehringer Ingelheim, Genentech, Inc., GlaxoSmithKline, KarmelSonix, Merck, Novartis, Perrigo, Sanofi-Aventis, Sunovion, Targacept, and TKL; he was a speaker, moderator, or both for the American College of Allergy, Asthma and Immunology. DS is employed by the RTI Health Solutions, which provides consulting and other research services. In this salaried position, he receives no payment or honoraria directly for services rendered. TM has received payments for serving on advisory boards for Boehringer-Ingelheim, Merck, and Novartis and lecture fees from Genentech, Merck, and TEVA. EA, KR, BT, and TAO are employees of Genentech, Inc. MB is an employee of Novartis Pharma AG.
Availability of data and materials
We provide qualified researchers access to individual patient level data through the clinical study data request platform (www.clincalstudydatarequest.com). Further details of Roche's Data Sharing Policy is available here (www.clinicalstudydatarequest.com/Study-Sponsors-Roche-Details).
Ethics approval and consent to participate
Studies were conducted in accordance with US Food and Drug Administration regulations, the International Conference on Harmonisation E6 Good Clinical Practice guidelines, the principles of the Declaration of Helsinki, and any other applicable country laws. Study protocols were reviewed and approved by each institutional review board and all patients provided informed consent before study entry.
Employees of the study sponsor are named as authors on this manuscript and contributed to the design of the study, the collection and interpretation of the data, and the preparation of this manuscript for submission.
Sensitivity analysis: changes in UPDD Sleep Interference score: a ASTERIA I, b ASTERIA II, and c GLACIAL. Arrows represent omalizumab dosing. Lower numbers represent better sleep. Least-squares means were derived from a repeated-measures model adjusted for baseline value (<median, ≥median), baseline weight (<80 kg, ≥80 kg), and weekly rescue medication (diphenhydramine) dose. Statistical significance is marked every 4 weeks to minimize the visual burden of the graph. However, the following endpoints demonstrated statistical significance, in addition to the ones marked on the graph: ASTERIA I: all time points for omalizumab 300 mg; weeks 2, 3, 7, 9, 10, 11, and 13 for omalizumab 150 mg; and weeks 1, 2, 5, 6, 10, 11, and 13 for omalizumab 75 mg; ASTERIA II: all time points for omalizumab 300 mg; weeks 1, 2, 3, 5, 6, 7, 9, 10, and 11 for omalizumab 150 mg; and weeks 1, 2, 5, 7, 9, 10, and 11 for omalizumab 75 mg; GLACIAL: all time points for omalizumab 300 mg. *p < 0.05; **p < 0.001; ***p < 0.01, versus placebo. UPDD: Urticaria Patient Daily Diary.
About this article
Cite this article
Gimenéz-Arnau, A.M., Spector, S., Antonova, E. et al. Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies. Clin Transl Allergy 6, 32 (2016). https://doi.org/10.1186/s13601-016-0120-0
- Chronic idiopathic urticaria
- Chronic spontaneous urticaria
- Sleep quality